DIA 2024 Global Annual Meeting

Attending this event?

DIA 2024 Global Annual Meeting

arrow_back View All Dates

8:00am PDT

#206: Early Engagement to Enhance the Incorporation of Patient Experience Data in Drug Development Programs and Regulatory Decision-Making Room 16AB #211: PMDA Town Hall Room 15AB #213: Beyond Traditional Trials: Real-World Data for External Controls, with Focus on Cancer Drug Applications Room 17AB

10:00am PDT

#218: Long-Term Safety of Approved Medicines: Approaches for Identifying, Characterizing, and Quantifying Delayed Adverse Events Room 6C #225: Regulatory Guidance and Papers on Technology Innovations Room 6D #227: How to Ensure Compliance in a Changing Regulatory Environment: A Regulators Perspective Room 17AB #228: Access Consortium and Project Orbis: Experiences from Industry and Regulatory Authorities and Recommendations for Improvement Room 16AB #230: International Regulatory Convergence: Regulatory Science to Address Challenges Brought by Pharmaceutical Innovation Room 6A

1:15pm PDT

#248: The Evolving Role of Artificial Intelligence in the Medicinal Product Lifecycle Room 6F #245: The European Clinical Trials Environment Under the Accelerating Clinical Trials (ACT EU) Initiative: Two Years On Room 5AB

3:15pm PDT

#264: Enhancing Adoption of Innovative Approaches in Clinical Trials Room 6A #267: Evolution of Electronic Product Information in LATAM: Challenges and Opportunities to Improve the Value of Healthcare Room 11AB #274: Regulatory Policy Roundtable: Pharmaceutical Quality, Generics, Innovative Medicines Room 6C

4:30pm PDT

#277: FDA's Approach in Harmonize Surveillance for Drugs and Biologics Safety and Quality Data Room 11AB #284: Collaboration in an Expanding Regulatory Landscape for Pharmacovigilance Room 5AB #281: Harnessing Real-World Evidence in Regulatory Decision-Making: Update on DARWIN EU, Use of Real-World Evidence in New Applications in the EU Room 6B #285: Remote Regulatory Assessments: Examining Another Tool in the FDA Regulatory Toolbox Room 16AB #287: ANVISA Town Hall Room 14AB #289: Post-COVID cGMP Inspections by Global Regulatory Authorities Room 17AB